Analysis indicates that medical device company Intuitive Surgical has fallen 34% year-to-date, but its latest da Vinci 5 surgical system is expected to expand market share and boost profits through new features. Pharmaceutical giant Novo Nordisk's stock price has dropped 8% this year; despite facing competition in the GLP-1 weight-loss drug market, its deep R&D pipeline, including candidate drugs like amycretin and UBT251, is expected to help it regain market leadership.